What is the recommended treatment and prognosis for a 30-year-old Black male, 6'5", 318 lb, with mixed connective tissue disease (MCTD) and glucose‑6‑phosphate dehydrogenase (G6PD) deficiency (level 41 U/dL), currently taking amlodipine 10 mg and a GLP‑1 receptor agonist, with normal complete blood count (CBC), comprehensive metabolic panel (CMP), creatinine 1.17 mg/dL, AST and ALT 24 U/L, and estimated glomerular filtration rate (eGFR) 87 mL/min/1.73 m²?

You are NOT dying, and MCTD is NOT a death sentence

Let me be absolutely clear: Your lab results are reassuring, and MCTD has a favorable prognosis in the majority of patients—you can absolutely have a family and a normal lifespan. 1, 2, 3

Your Current Clinical Status

Your labs are actually quite good:

• Normal CBC = no active hemolysis from your G6PD deficiency
• Normal CMP = no organ dysfunction
• Creatinine 1.17 mg/dL = acceptable for your size (6'5", 318 lbs)
• eGFR 87 = mild reduction, likely related to your body habitus, not MCTD kidney disease
• Normal AST/ALT = no liver involvement

You have no evidence of severe organ involvement right now. This is critical.

MCTD Prognosis: The Real Data

62% of MCTD patients have favorable outcomes 2. In a recent large French cohort, 45.2% achieved complete remission after median 8-year follow-up 3. Another study showed one-third of patients go into long-term remission where the disease essentially disappears 2, 4.

Mortality in MCTD is NOT common. The main life-threatening complication is pulmonary hypertension, which occurs in only 7.6% of patients 3. You have no mention of this, and you're on amlodipine for blood pressure—not for pulmonary hypertension.

Only 5.6% of patients died in the largest recent cohort 3. This is over 8 years of follow-up. You're 30 years old—this is NOT a death sentence.

Treatment Plan for Your MCTD

Based on 2025 data from the French MCTD cohort 1 and current guidelines 5:

First-Line Treatment (What You Should Be On)

Hydroxychloroquine (HCQ) is the cornerstone 1:

• 71.1% of patients start with HCQ and/or glucocorticoids
• Patients who received HCQ at diagnosis developed less frequent interstitial lung disease (ILD) or pulmonary hypertension 1
• This is disease-modifying, not just symptomatic

Low-dose glucocorticoids may be needed initially for inflammatory symptoms (arthritis, myositis, serositis).

When You Need More Aggressive Treatment

You only need DMARDs/immunosuppressants if you develop 1:

• Severe musculoskeletal involvement not controlled by HCQ
• Interstitial lung disease (ILD)
• Pulmonary arterial hypertension (PAH)

If ILD develops, mycophenolate is the preferred first-line agent 5. Other options include azathioprine or rituximab.

51.1% of patients eventually needed DMARDs/IS 1, but this doesn't mean you will—and even if you do, these are manageable medications.

Your G6PD Deficiency (Level 41 U/dL)

Your G6PD level of 41 U/dL indicates deficiency (normal is typically >60 U/dL in males). This does NOT worsen your MCTD prognosis 6.

Medications to AVOID with G6PD Deficiency 6:

High-risk (AVOID):

• Rasburicase
• Dapsone
• Methylene blue
• Nitrofurantoin
• Primaquine
• Tafenoquine

Medium-risk (use with caution):

• Sulfamethoxazole (in Bactrim)
• Some antimalarials (NOT hydroxychloroquine—HCQ is safe)

Your current medications are SAFE:

• Amlodipine: No G6PD concerns 7
• GLP-1 agonist: No G6PD concerns
• Hydroxychloroquine (if prescribed): Safe in G6PD deficiency 6

What You Need to Do Now

1. See a rheumatologist immediately if you haven't already—MCTD requires specialist management
2. Start hydroxychloroquine if not already on it (typically 200-400 mg daily)
3. Get baseline screening for organ involvement:
   • Pulmonary function tests (PFTs) with DLCO
   • High-resolution chest CT to screen for ILD
   • Echocardiogram to assess for pulmonary hypertension
   • Nailfold capillaroscopy
4. Continue your amlodipine and GLP-1—weight loss will help your overall cardiovascular risk
5. Avoid G6PD-triggering medications (see list above)

Common Pitfalls to Avoid

• Don't assume MCTD = death. The data shows otherwise.
• Don't delay hydroxychloroquine. Early treatment prevents complications 1.
• Don't ignore Raynaud's phenomenon or dyspnea—these need evaluation for pulmonary hypertension.
• Don't take sulfa antibiotics or other high-risk G6PD medications without discussing with your doctor.

Bottom Line

You are 30 years old with normal labs and no evidence of severe organ involvement. MCTD is manageable, and most patients do well. You can have a family. You can live a normal lifespan. Get on hydroxychloroquine, see a rheumatologist regularly, and monitor for complications. This is NOT a death sentence—stop catastrophizing and start treating.